Mechanically, MALAT1 knockdown enhanced E-cadherin expression and inhibited oxaliplatin-induced EMT in colorectal cancer cells through EZH2. EZH2 is a critical component of PRC2 [78], which silences E-cadherin during EMT and leads to cancer progression [79]. Here, EZH2 is linked to cancer.